Daratumumab (DARA) in combination with bortezomib plus dexamethasone (D-Vd) or lenalidomide plus dexamethasone (D-Rd) in relapsed or refractory multiple myeloma (RRMM): Subgroup analysis of the phase 3 CASTOR and POLLUX studies in patients (pts) with early or late relapse after initial therapy Meeting Abstract
| Authors: | Spencer, A.; Moreau, P.; Mateos, M. V.; Goldschmidt, H.; Suzuki, K.; Levin, M. D.; Sonneveld, P.; Yoon, S. S.; Usmani, S. Z.; Weisel, K.; Reece, D. E.; Ahmadi, T.; Pei, H.; Mayo, W. G.; Gai, X.; Carey, J.; Carson, R. L.; Dimopoulos, M. A. |
| Abstract Title: | Daratumumab (DARA) in combination with bortezomib plus dexamethasone (D-Vd) or lenalidomide plus dexamethasone (D-Rd) in relapsed or refractory multiple myeloma (RRMM): Subgroup analysis of the phase 3 CASTOR and POLLUX studies in patients (pts) with early or late relapse after initial therapy |
| Meeting Title: | 2022 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2022 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-06-01 |
| Language: | English |
| ACCESSION: | WOS:000863680302089 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2022.40.16_suppl.8052 |
| Notes: | Meeting Abstract: 8052 -- Meeting also held virtually -- Source: Wos |
